CKPT - Checkpoint Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Checkpoint Therapeutics, Inc.

2 Gansevoort Street
9th Floor
New York, NY 10014
United States
781-652-4500
http://www.checkpointtx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees7

Key Executives

NameTitlePayExercisedYear Born
Mr. James F. Oliviero III, C.F.A., CFACEO, Pres & Director831.25kN/A1976
Mr. William Garrett GrayVP of Fin. & Accounting, Principal Financial Officer and Corp. Sec.235.81kN/A1987
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in the phase 1/2 clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and CK-301, a programmed death ligand-1 (PD-L1), which is in phase I clinical trial in patients with selected recurrent or metastatic cancers. It also develops CK-103, a small molecule inhibitor of BET bromodomains; and CK-302, a human agonistic antibody for oncology indications. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the anti-PD-L1 antibodies anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Corporate Governance

Checkpoint Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.